Grants per year
- 50 - 75 out of 1,381 results
Search results
-
Finished
Prot #JCAR017-FOL-001: A Phase 2, Open-Label, Single-Arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects with Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma (NHL) (Transcend FL)
ICON Clinical Research, LLC, Celgene Corporation
7/27/20 → 7/27/23
Project: Research project
-
Prot #ETCTN 10107/MC1721: Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and MK-3475 (Pembrolizumab) Compared to MK-3475 (Pembrolizumab) Alone for Mesothelin-Positive Malignant Pleural Mesothelioma
Leidos Biomedical Research, Inc., Bayer HealthCare Pharmaceuticals, Inc.
7/21/20 → 8/30/21
Project: Research project
-
Prot #RM-110: Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability and Efficacy of Rivoceranib or Trifluridine/Tipiracil as Monotherapies and Rivoceranib and Trifluridine/Tipiracil as Combination Therapy in Subjects with Metastatic Colorectal
Medpace Clinical Research LLC, Elevar Therapeutics, Inc.
7/16/20 → 7/16/23
Project: Research project
-
Prot #RMC-4630-02: A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 with Cobimetinib in Adult Participants with Relapsed/Refractory Solid Tumors and a Phase 1b Study of RMC-4630 with Osimertinib
PPD Investigator Services, LLC, Revolution Medicines, Inc.
7/7/20 → 7/7/23
Project: Research project
-
Par3 deficiency promotes fatty replacement in chronic pancreatitis
American Pancreatic Association
7/1/20 → 5/31/21
Project: Research project
-
Prot #OMS-I103: The PISCES Study: A Multicenter Phase 2, Open-Label Study of Intratumoral Tavokinogene Telseplasmid (tavo, pIL-12) plus Electroporation in Combination with Intravenous Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressin
Precision Oncology, LLC, OncoSec Medical Incorporated
7/1/20 → 7/1/23
Project: Research project
-
A Novel ULK1 Pathway as a New Therapeutic Target in Melanoma
7/1/20 → 6/30/23
Project: Research project
-
Targeting CysLTR1 in triple negative breast cancer
Zhang, B. & Cristofanilli, M.
U.S. Army Medical Research and Materiel Command
7/1/20 → 6/30/23
Project: Research project
-
Mechanisms of transformation and therapy resistance in myelodysplastic syndrome and acute myeloid leukemia
Crispino, J. D.
7/1/20 → 6/30/21
Project: Research project
-
COVID19: Production of protein array for serum antibody screening
Platanias, L. C., Achenbach, C. J., Hultquist, J. F. & Satchell, K. J.
7/1/20 → 1/31/22
Project: Research project
-
Engineering CpG Deoxynucleotide-Conjugated Gold Nanoparticles for Enhanced Anti-Lymphoma Effects
7/1/20 → 6/30/22
Project: Research project
-
Combinational DC vaccines and interventional Irreversible Electroporation for pancreatic ductal adenocarcinoma therapy.
Zhang, Z., Benson III, A. B., Ji, P., Salem, R. & Zhang, Z.
6/1/20 → 5/31/21
Project: Research project
-
Prot #SMX 18-001: An Open-label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2−Breast Cancer with an ESR1 Mutat
Shah, A. N.
Linical Americas, Sermonix Pharmaceuticals, Inc.
5/28/20 → 5/28/23
Project: Research project
-
Prot #BNT411-01: Phase 1/2a, First-In-Human, Open-label, Dose-escalation Trial With Expansion Cohorts To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Efficacy Of BNT411 As A Monotherapy In Patients With Solid Tumors And In Combinat
ICON plc, BioNTech Small Molecules GmbH
5/27/20 → 5/27/23
Project: Research project
-
Prot #RAIN-701: A Phase 2 Study to Evaluate the Clinical Activity of Tarloxotinib in Patients with Non-Small Cell Lung Cancer that Harbors Either an EGFR Exon 20 Insertion or a HER2-Activating Mutation and Other Advanced Solid Tumors with NRG1/ERBB Family
NCGS, Inc., Rain Therapeutics Inc.
4/29/20 → 4/29/23
Project: Research project
-
Prot #NU FC19L02: TH-138: Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, with or without Atezolizumab in Stage IV Non-squamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked
National Comprehensive Cancer Network, Genentech, Inc.
4/21/20 → 4/21/23
Project: Research project